Long-term evolution of renal function in patients with type 2 diabetes mellitus: A registry-based retrospective cohort study

BMJ Open

Volumn 3, Issue 12, 2013, Pages

  Goderis, Geert ^a   Van Pottelbergh, Gijs ^a,b   Truyers, Carla ^a   Van Casteren, Viviane ^c   De Clercq, Etienne ^b   Van Den Broeke, Carine ^a   Buntinx, Frank ^a,d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

AGE; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE DURATION; DRUG USE; FEMALE; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 84892575333     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004029     Document Type: Article

References (34)

1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
2. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51. (Pubitemid 34984606)
3. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63. (Pubitemid 38392981)
4. Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006;3:A57.
5. Perico N, Remuzzi G. Chronic kidney disease: a research and public health priority. Nephrol Dial Transplant 2012;27(Suppl 3):iii19-26.
6. Weiner DE. Public health consequences of chronic kidney disease. Clin Pharmacol Ther 2009;86:566-9.
7. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
8. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005;46:871-80. (Pubitemid 41505461)
9. Kovesdy CP. Rate of kidney function decline associates with increased risk of death. J Am Soc Nephrol 2010;21:1814-16.
10. Al Aly Z, Zeringue A, Fu J, et al. Rate of kidney function decline associates with mortality. J Am Soc Nephrol 2010;21:1961-9.
11. Couser WG. Chronic kidney disease the promise and the perils. J Am Soc Nephrol 2007;18:2803-5.
12. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81:442-8.
13. Altemtam N, Russell J, El Nahas M. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant 2011;27:1847-54.
14. Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and HbA1c. Diabetes Care 2002;25:275-8.
15. Martin U, Holder R, Hodgkinson J, et al. Inter-arm blood pressure differences compared with ambulatory monitoring: a manifestation of the 'white-coat' effect? Br J Gen Pract 2013;63:e97-103.
16. Van Pottelbergh G, Bartholomeeusen S, Buntinx F, et al. The evolution of renal function and the incidence of end-stage renal disease in patients aged ?50 years. Nephrol Dial Transplant 2012;27:2297-303.
17. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007;18:2758-65. (Pubitemid 47531203)
18. Obrador GT, Garcia-Garcia G, Villa AR,, et al Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) Mexico and comparison with KEEP US. Kidney Int Suppl 2010;77: S2-8.
19. Stevens LA, Li S, Wang C, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010;55 (3 Suppl 2):S23-33.
20. Detournay B, Simon D, Guillausseau PJ, et al. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab 2012;38:102-12.
21. Al Aly Z, Cepeda O. Rate of change in kidney function and the risk of death: the case for incorporating the rate of kidney function decline into the CKD staging system. Nephron Clin Pract 2011;119: c179-85.
22. Turin TC, Coresh J, Tonelli M, et al. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant 2012;27:3835-43.
23. Lee P, Johansen K, Hsu Cy. End-stage renal disease preceded by rapid declines in kidney function: a case series. BMC Nephrol 2011;12:5.
24. Li PK, Cheng YL. Therapeutic options for preservation of residual renal function in patients on peritoneal dialysis. Perit Dial Int 2007;27 (Suppl 2):S158-63. (Pubitemid 350047694)
25. Vupputuri S, Batuman V, Muntner P, et al. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 2003;42:1144-9. (Pubitemid 37549069)
26. Mimran A. Consequences of elevated pulse pressure on renal function. J Hypertens Suppl 2006;24:S3-7. (Pubitemid 44336812)
27. Arulkumaran N, Diwakar R, Tahir Z, et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010;23:189-93.
28. Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 2012;7:401-8.
29. Cummings DM, Larsen LC, Doherty L, et al. Glycemic control patterns and kidney disease progression among primary care patients with diabetes mellitus. J Am Board Fam Med 2011;24:391-8.
30. Lin J, Hu FB, Mantzoros C, et al. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 2010;53:263-7.
31. Bartholomeeusen S, Truyers C, Buntinx F. Ziekten in de huisartspraktijk in Vlaanderen 1994-2008. Leuven: ACCO, 2010.
32. Van der Heyden J, Mimilidis H, Bartholomeeusen S, et al. Diabetesprevalentie in België: vergelijking van beschikbare data. Vlaams tijdschrift voor Diabetol 2012;2:6-8.
33. Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int 1997;51:850-4. (Pubitemid 27157972)
34. Nosadini R, Velussi M, Brocco E, et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000;49:476-84. (Pubitemid 30131795)